Compare Biogen Inc (BIIB) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Prudential PLC — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Prudential PLC trades at $28.65 (market cap $35.11B). The key difference: Prudential PLC is the larger of the two by market cap, and Prudential PLC pays a 1.86% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PUK | |
|---|---|---|
Market Cap | $28.34B | $35.11B |
Sector | Health | Financials |
52-Week High | $216.63 | $33.61 |
52-Week Low | $122.68 | $24.65 |
Enterprise Value | $30.62B | $36.55B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Prudential (PUK) trades at $28.40, up 0.96% with bullish technical signals from moving averages. The stock shows strong fundamentals with a P/E of 9.25, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q2 and Q4 2025, while analyst consensus leans bullish with 50% buy ratings. Positive news includes JP Morgan's catalyst watch ahead of August results and strategic expansion in India.
Outlook remains positive with improving cash flow trends and debt reduction. Key opportunities include Asia growth exposure and strong profitability metrics. Risks include China regulatory uncertainty and Japan sales suspension impacts. The stock presents value with attractive valuation multiples and analyst support for upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
